Recent Updates
Recently added Catalysts

Cytokinetics, Incorporated

CYTKFDA catalysts, PDUFA dates & pipeline intelligence
$52.85
▼ -3.29 · -5.85%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CYTK financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $53.5552W HIGH $88.31
Volume
716.42 K
Value Traded
38.54 M
Short % Float
13.34%
Days to Cover
14.2
-3.84%Week
-15.36%1 Month
-30.11%3 Month
-29.47%6 Month
+233.8%5 Year
-14.51%All Time

Cash Data

Unlock CYTK cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
7.36 B
EPS (TTM)
-5.58
P/E Ratio
-
Ent. Value
6.23 B
Total Shares
139.30 M
Float Shares
134.41 M
Insiders
3.51%
Institutions
115.81%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
sNDA Submission
aficamten
adult patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)
sNDASmall MoleculesCardiovascular
Unlock every CYTK catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CYTK Catalyst Timeline

Dated clinical, regulatory and corporate events for Cytokinetics, Incorporated

Catalyst Timeline

Dated clinical, regulatory & corporate events for Cytokinetics, Incorporated

1233Total events
14Upcoming
278Tier-1 (high impact)
2015 to 2027Coverage

Upcoming catalysts 2

T2sNDA Submission
Subscribe to view catalyst details
AficamtenApproved
T1NDA Submission
Subscribe to view catalyst details
AficamtenApproved

Event history 50

▲Reimbursement / PricingAficamtenApprovedPost-Market
HAS Transparency Committee grants MYQORZO ASMR III rating and significant SMR for oHCM
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲Late-BreakerAficamtenApprovedPresentation
Late-breaking oral abstract: aficamten CMR sub-study data in nHCM presented at HCMS/AHA 2026
non-obstructive hypertrophic cardiomyopathysource ↗
▲Poster PresentationAficamtenApprovedPresentation
Poster: FOREST-HCM long-term LV systolic dysfunction data with aficamten in oHCM at HCMS/AHA 2026
obstructive hypertrophic cardiomyopathysource ↗
▲PublicationAficamtenApprovedPresentation
FOREST-HCM long-term safety data published in Journal of Cardiac Failure
obstructive hypertrophic cardiomyopathysource ↗
◆Late-BreakerAficamtenApprovedPresentation
Late-breaking oral abstract on aficamten effect on cardiac structure and function in nHCM (ACACIA-HCM CMR)
Nonobstructive Hypertrophic Cardiomyopathysource ↗
◆Poster PresentationAficamtenApprovedPresentation
Poster on left ventricular systolic dysfunction in long-term aficamten therapy for oHCM (FOREST-HCM analysis)
Obstructive Hypertrophic Cardiomyopathysource ↗
●Quarterly UpdateCorporate
Reported third quarter 2026 financial results and business update
▲Canada ApprovalAficamtenApprovedEx-US Regulatory
Health Canada approves MYQORZO (aficamten) for symptomatic oHCM
symptomatic obstructive hypertrophic cardiomyopathy (oHCM), NYHA class II-IIIsource ↗
▲Late-BreakerAficamtenApprovedPresentation
Late breaking presentation of comprehensive exercise performance analysis from ACACIA-HCM at HFSA 2026
Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)source ↗
●Oral PresentationAficamtenApprovedPresentation
Presentation of dose titration and safety data from ACACIA-HCM at HFSA 2026
Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)source ↗
Unlock the full CYTK catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CYTK actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-16MYQORZO (aficamten) PDUFA Date ApprovedPDUFA
Unlock 14 more CYTK historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 8%
Small Cap
(rank 59 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
MYQORZO
Showing 12 of 20 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
CK-4021586 Small MoleculesNCT06793371Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)Phase 2 RECRUITING 60Sep 1, 2026
Aficamten Small MoleculesNCT06081894Symptomatic Non-Obstructive Hypertrophic CardiomyopathyPhase 3 ACTIVE NOT_RECRUITING 500Nov 1, 2026
Aficamten Small MoleculesMarketedNCT06412666Symptomatic Obstructive Hypertrophic CardiomyopathyApproved ACTIVE NOT_RECRUITING 65Jan 1, 2030
Aficamten Small MoleculesMarketedNCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)Approved ENROLLING BY_INVITATION 900Mar 1, 2029
Omecamtiv mecarbil Small MoleculesNCT01380223Heart FailurePhase 3 COMPLETED 10,705Apr 1, 2006
Omecamtiv mecarbil Small MoleculesCompletedNCT02695420Heart Failure With Reduced Ejection FractionPhase 3 COMPLETED 357May 8, 2017
CK-1827452 Small MoleculesCompletedNCT00941681Heart FailurePhase 2 COMPLETED 174Oct 1, 2009
Omecamtiv mecarbil Small MoleculesCompletedNCT04175808QT Intervals ChangesPhase 1 COMPLETED 70Mar 4, 2020
Reldesemtiv Small MoleculesCompletedNCT03160898Amyotrophic Lateral SclerosisPhase 2 COMPLETED 458Mar 7, 2019
Aficamten Small MoleculesMarketedNCT05767346Obstructive Hypertrophic Cardiomyopathy (oHCM)Approved COMPLETED 457Mar 28, 2025
CK-3773274 Small MoleculesMarketedNCT04219826Hypertrophic Cardiomyopathy (HCM)Approved COMPLETED 96Feb 28, 2023
CK-3773274- Granules in Small MoleculesMarketedNCT03767855Symptomatic Obstructive Hypertrophic CardiomyopathyApproved COMPLETED 114Jan 3, 2020
Unlock the CYTK pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CYTK program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
aficamten hypertrophic cardiomyopathy2026-11-09LVMI reduction: statistically significant (p<0.001); KCCQ OSS improvement: 4.0-point greater improvement; improvement rate: 33.7% vs. 22.5%; deterioration rate: 7.4% vs. 13.3%Read MoreCytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026Read More
Scroll for more · summaries link to the source press release
Unlock every CYTK trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CYTK insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
PARSHALL B LYNNEDirectorSell -2,445 8,339 held$54.17 11/09/2026
Unlock the full CYTK insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Avoro Capital Advisors LLC 3.8 % (72.7 %) 425.95 M 5.00 M 50% ( 1.67 M)
Unlock every fund holding CYTK
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CYTK
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CYTK ownership
Insider and institutional ownership, quarter by quarter.

CYTK Short Interest

Shares sold short, counted twice a month.

13.34%
Short % of Float
of tradable shares sold short
17.9M
Shares Sold Short
-3.7% vs prior count
14.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Unlock CYTK short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock CYTK option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CYTK option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CYTK options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CYTK ranks across every disease it competes in

Competitive Position is a premium feature
See how CYTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CYTK News

CYTK
Nov 16, 2026
CYTKFDA Updates
▼ -5.8%today

Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM

Cytokinetics announced that the FDA approved an update to MYQORZO's prescribing information, incorporating data from the Phase 3 MAPLE-HCM trial. This trial demonstrated that MYQORZO significantly outperformed the beta-blocker metoprolol in improving exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy. MYQORZO is now the only cardiac myosin inhibitor with comparative effectiveness data in its U.S. label.

Read more →
CYTK
Nov 10, 2026
CYTKFDA Updates

MYQORZO® (aficamten) Receives ASMR III Rating from the HAS (French National Authority for Health) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy in Adults

Cytokinetics announced that MYQORZO® (aficamten) received an ASMR III rating from the French HAS for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. This rating reflects the drug's significant medical benefit and is based on positive results from Phase 3 trials. The decision aims to enhance patient access to this treatment in France.

Read more →
CYTK
Nov 9, 2026
CYTKConferences/Events

Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

Cytokinetics presented new data on aficamten at the HCMS Scientific Sessions 2026. The findings indicate significant improvements in cardiac structure and patient-reported health status in hypertrophic cardiomyopathy patients. Notably, aficamten demonstrated favorable cardiac remodeling and a strong safety profile, with no serious adverse events related to heart failure.

Read more →
CYTK
Nov 4, 2026
CYTKGeneral
▼ -12.7%on this newsshared move

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

Cytokinetics reported strong Q3 2026 results with $44.5 million in net revenue from MYQORZO. The company plans to submit a Supplemental NDA for aficamten in non-obstructive HCM by Q4 2026. Positive results from the ACACIA-HCM trial support its potential approval. However, the company reported a net loss of $190.1 million for the quarter.

Read more →
CYTK
Nov 3, 2026
CYTKConferences/Events

Cytokinetics to Participate in November Investor Conferences

Cytokinetics announced participation in several investor conferences throughout November 2026. Key events include fireside chats at the Stifel, UBS, Jefferies, and Evercore conferences. The company continues to advance its drug pipeline, including the planned submission of a Supplemental New Drug Application for aficamten in Q4 2026.

Read more →
CYTK
Nov 2, 2026
CYTKConferences/Events

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

Cytokinetics will present three studies at the HCMS Scientific Sessions on November 6, 2026. Two of the presentations will focus on Aficamten's effects on non-obstructive hypertrophic cardiomyopathy. The company also plans to submit a Supplemental New Drug Application for Aficamten following positive trial results.

Read more →
CYTK
Oct 21, 2026
CYTKConferences/Events

Cytokinetics to Announce Third Quarter Results on November 4, 2026

Cytokinetics will announce its third quarter results on November 4, 2026, at 4:00 PM ET. A conference call will follow at 4:30 PM ET to discuss the financial results and business updates. The company is advancing its pipeline, including aficamten, which has shown positive results in a Phase 3 trial.

Read more →
CYTK
Oct 19, 2026
CYTKGeneral

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics announced the grant of stock options and restricted stock units to 29 new employees as an inducement for employment. The RSUs will vest over three years, while the stock options have a four-year vesting schedule. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to expanding its workforce.

Read more →
CYTK
Oct 19, 2026
CYTKFDA Updates

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics has received Health Canada approval for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adults. This marks the fifth regulatory approval for MYQORZO within a year, following approvals in the U.S., China, and Europe. The approval is based on positive results from the pivotal Phase 3 SEQUOIA-HCM trial, demonstrating significant improvements in exercise capacity and symptoms. MYQORZO is a well-tolerated treatment option, although it comes with a risk of heart failure due to its effects on left ventricular ejection fraction.

Read more →
CYTK
Oct 12, 2026
CYTKPhases

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Cytokinetics presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting 2026, highlighting the efficacy and safety of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The analyses showed significant improvements in exercise performance and treatment effects. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

Read more →
CYTK
Oct 2, 2026
CYTKConferences/Events

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

Cytokinetics has announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026, including two Late Breaking Clinical Research presentations. These presentations will focus on the efficacy of Aficamten in treating non-obstructive hypertrophic cardiomyopathy. The meeting will take place in Phoenix, AZ from October 9 to 12, 2026. Cytokinetics continues to advance its pipeline of cardiac treatments.

Read more →
CYTK
Sep 30, 2026
CYTKPhases

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics has launched the ASPEN-HCM study to evaluate MYQORZO (aficamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy. This multicenter, observational study aims to generate real-world evidence on the safety and effectiveness of MYQORZO over 12 to 36 months. The study will assess various clinical outcomes and healthcare resource utilization.

Read more →
CYTK
Sep 14, 2026
CYTKGeneral

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

Cytokinetics has announced the ninth annual Communications Grant Program aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy and heart failure. The program will provide grants to enhance communication efforts and community engagement. Applications are open until October 2, 2026, with recipients announced in January 2027.

Read more →
CYTK
Sep 2, 2026
CYTKConferences/Events

Cytokinetics to Participate in September Investor Conferences

Cytokinetics, Inc. announced its participation in several investor conferences in September 2026, including the Citi BioPharma Conference and the Morgan Stanley Global Healthcare Conference. The management team will engage in fireside chats to discuss the company's advancements in cardiac muscle therapies. Cytokinetics is also preparing to submit a Supplemental New Drug Application for aficamten following positive Phase 3 trial results.

Read more →
CYTK
Aug 29, 2026
CYTKPhases

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics presented additional results from the ACACIA-HCM and MAPLE-HCM trials at the ESC Congress 2026. The findings indicate that aficamten significantly improves cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy (HCM) and outperforms metoprolol in obstructive HCM. These results expand the evidence supporting aficamten's potential use across various HCM patient populations.

Read more →
CYTK
Aug 28, 2026
CYTKPhases
▼ -7.5%on this newsshared move

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

Cytokinetics announced positive results from the ACACIA-HCM trial, the first Phase 3 study to show significant improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met its dual primary endpoints, leading the company to plan a supplemental New Drug Application to the FDA. The results were presented at the ESC Congress 2026 and published in The New England Journal of Medicine.

Read more →
CYTK
Aug 20, 2026
CYTKConferences/Events

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics has announced its participation in the European Society of Cardiology Congress 2026, featuring a Hot Line presentation on the ACACIA-HCM trial's positive results for aficamten in non-obstructive hypertrophic cardiomyopathy. The company will also host an investor event to discuss these findings. Presentations will take place from August 28-31 in Munich, Germany.

Read more →
CYTK
Aug 6, 2026
CYTKGeneral
▼ -5.7%on this news

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cytokinetics reported a net product revenue of $25 million for MYQORZO in Q2 2026, indicating strong commercial momentum. The company plans to submit a Supplemental NDA for aficamten in non-obstructive HCM by Q4 2026, following positive results from the ACACIA-HCM trial. Additionally, Cytokinetics is expanding its market presence internationally, with launches in Germany and approvals in the UK.

Read more →

About Cytokinetics, Incorporated

South San Francisco, CA 673 employees cytokinetics.com
Headquarters350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE
Trade the next CYTK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime